Society for Immunotherapy of Cancer

Submit your exciting new clinical Late-breaking research for SITC 2025! The deadline to submit research for Late-breaking Abstracts – Clinical Only (LBAs) is Sept. 15, 2025.

View new LBA guidelines: www.sitcancer.org/2025/abstrac...

#SITC25 #immunotherapy #OncSky #MedSky

It is an honor to present Francesco Marincola of Translational and Advanced Medicine (TAM) Global with the 2025 SITC Lifetime Achievement Award. Thank you for your unwavering support of SITC and the lasting impact you’ve made on our society. LEARN MORE: sitcancer.org/aboutsitc/aw...

Don’t miss our 40th Anniversary Annual Meeting and Pre-Conference Programs. Thank you to the SITC 2025 Keynote, Dr. Jennifer Wargo, and & Smalley Lecturer, Dr. Ira Mellman. Be sure to attend these presentations and more at #SITC25.

Register today: www.mylibralounge.com/sites/sitc20...

It is an honor to present Francesco Marincola of Translational and Advanced Medicine (TAM) Global with the 2025 SITC Lifetime Achievement Award. Thank you for your unwavering support of SITC and the lasting impact you’ve made on our society. LEARN MORE: sitcancer.org/aboutsitc/aw...

At #SITC25 Ira Mellman of the @parkerici.bsky.social and Medici Therapeutics will be honored for the 2025 Richard V. Smalley Memorial Award and Lectureship! He will give a presentation on Nov. 8 – join virtually or attend in person. www.sitcancer.org/2025/home

New Journal for ImmunoTherapy of Cancer article: Anti-galectin-9 therapy synergizes with EGFR inhibition to reprogram the tumor microenvironment and overcome immune evasion https://bit.ly/4lBt5zj 🧪 #JITC #MedSky #ImmunoSky #tumor #OncSky Background Despite the remarkable clinical outcomes of epidermal growth factor receptor (EGFR)-targeted therapies in patients with lung cancer, therapeutic resistance eventually develops. This study e...

New Journal for ImmunoTherapy of Cancer article: Anti-galectin-9 therapy synergizes with EGFR inhibition to reprogram the tumor microenvironment and overcome immune evasion bit.ly/4lBt5zj 🧪

#JITC #MedSky #ImmunoSky #tumor #OncSky

SITC is excited to recognize Dr. Catherine J. Wu of ‪@danafarber.bsky.social‬ on receiving the 2026 Richard V. Smalley Memorial Award and Lectureship. Dr. Wu will be honored at next year’s 41st Annual Meeting with a keynote lecture. LEARN MORE: sitcancer.org/aboutsitc/aw...

Three weeks left to apply for the NCI Immunotherapy Fellowship. Get introduced to multiple clinical cancer immunotherapeutic approaches in this visiting fellowship. Applications are due Aug. 19. Apply here: sitcancer.org/professional... #Fellowship #IO #SITC

Congratulations to Dr. Matthew Rosenthal of @gladstoneinst.bsky.social‬, recipient of the 2025 National Cancer Institute Immunotherapy Fellowship, a 1-year, visiting #Fellowship! www.sitcancer.org/professional...

Exciting new #immunotherapy research! jitc.bmj.com/content/13/7...

#JITC #ImmunoSky

Human papillomavirus negative head and neck squamous cell carcinoma (HNSCC), the risk of which is 700-fold higher in Fanconi anemia, is associated with a dismal prognosis and efficacious therapies that can overcome suppressive tumor microenvironment
Here, Khaw Felices & Miller advance new TriKE

Congratulations to Dr. Ivan Susin Pires of Brigham and Women's Hospital, recipient of the 2025 SITC Cancer Immunotherapy Fellowship, a 1-year, $100,000 SITC Fellowship! #fellowship #ForwardFund www.sitcancer.org/professional...

Congratulations to Dr. Anna Ralser of @gladstoneinst.bsky.social‬, recipient of the 2025 SITC-Merck Cancer Immunotherapy Clinical Fellowship, a 1-year, $100K SITC Fellowship! #fellowship #ForwardFund www.sitcancer.org/professional...

New Journal for ImmunoTherapy of Cancer review: Tumor organoids in immunotherapy: from disease modeling to translational research https://bit.ly/40ZwMGH 🧪 #JITC #ImmunoSky #OncSkt #MedSky

New Journal for ImmunoTherapy of Cancer review: Tumor organoids in immunotherapy: from disease modeling to translational research bit.ly/40ZwMGH 🧪

#JITC #ImmunoSky #OncSkt #MedSky

Drs. John Haanen @nkinl.bsky.social, Kedar Kirtane @moffittnews.bsky.social, @jguerriero.bsky.social Brigham and Women’s Hospital, Parameswaran Hari, Obsidian Therapeutics & @jasonlukemd.bsky.social @news.upmc.com explore cell therapies beyond CAR T cells at #SITC25! Learn more: ow.ly/FfmJ50WuJ5k

Check out the publication of a new manuscript titled, “Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee” on @jitcancer
: jitc.bmj.com/content/13/6...

Congratulations to Dr. Mohamad Ali Najia of @bostonchildrens.bsky.social recipient of the 2025 SITC-Genmab Cancer Immunotherapy in Hematologic Malignancies: DLBCL, FL, and CLL Translational Fellowship, a 1-year, $100K SITC Fellowship! #ForwardFund www.sitcancer.org/professional...

Thank you to our partners and participants for making the WIC-APAC 2025 a success! This collaborative effort continues to build lasting partnerships and spark meaningful dialogue. Continue the conversation at SITC 2025. Join international investigators at the 6th WIC Symposium: https://t.co/PC7hf96wBZ 🧪

Thank you to our partners and participants for making the WIC-APAC 2025 a success! This collaborative effort continues to build lasting partnerships and spark meaningful dialogue.

Continue the conversation at SITC 2025. Join international investigators at the 6th WIC Symposium: t.co/PC7hf96wBZ 🧪

Manage non-small cell lung cancer in the perioperative, metastatic, and second-line setting with insights from leading experts! Join us Sept. 12 for a FREE live virtual cancer #immunotherapy program, ACI: A Focus on Lung Cancers. Learn more and register now: https://t.co/H0ilUVJjEr 🧪

Manage non-small cell lung cancer in the perioperative, metastatic, and second-line setting with insights from leading experts! Join us Sept. 12 for a FREE live virtual cancer #immunotherapy program, ACI: A Focus on Lung Cancers.

Learn more and register now: t.co/H0ilUVJjEr 🧪

Please join us in congratulating the recipients of the 2025 SITC #ForwardFund Fellowships. Through dedicated funding, these fellowships help support the next generation of cancer immunotherapy professionals. Learn more about the recipients here: www.sitcancer.org/professional...

New Journal for ImmunoTherapy of Cancer commentary: Commentary on differential impact of TIM-3 ligands on NK cell function https://bit.ly/4kEJNg3 🧪 #JITC #ImmunoSky #MedSky #OncSky

New Journal for ImmunoTherapy of Cancer commentary: Commentary on differential impact of TIM-3 ligands on NK cell function bit.ly/4kEJNg3 🧪

#JITC #ImmunoSky #MedSky #OncSky

New Journal for ImmunoTherapy of Cancer review: Therapeutic potential of targeting LAG-3 in cancer bit.ly/4nHQO2h

#JITC #ImmunoSky #OncSky #MedSky

Stay current with global #IO standards and discover cutting-edge science at #SITC25 in National Harbor, MD or virtually Nov. 5–9! Translate the latest breakthroughs to patient care with insights from international leaders. Early registration ends Aug. 13: https://sitcancer.org/2025/home 🧪

Stay current with global #IO standards and discover cutting-edge science at #SITC25 in National Harbor, MD or virtually Nov. 5–9! Translate the latest breakthroughs to patient care with insights from international leaders.

Early registration ends Aug. 13: sitcancer.org/2025/home 🧪

Hello, can we be added to this starter pack? Thanks!

Catch the latest cancer #immunotherapy research and updates with the July #JITC Digest! Get key takeaways on launching IO therapies with insights from the SITC Biotech Strategic Meeting at the NYSE. Access panel highlights and expert perspectives! https://ow.ly/lhu250WqB30 🧪

Catch the latest cancer #immunotherapy research and updates with the July #JITC Digest! Get key takeaways on launching IO therapies with insights from the SITC Biotech Strategic Meeting at the NYSE.

Access panel highlights and expert perspectives! ow.ly/lhu250WqB30 🧪

#OncSky #ImmunoSky

The 2026 Spring Scientific: Enhancing Cellular Therapies with Next-generation #IO Molecules will be on March 25-27! Registration opens Aug. 18! SITC will bring together experts to address combining next-generation IO agents with #cellular #therapies to treat #cancer! - sitcancer.org/SpringScientific

NCI and the Society for Immunotherapy of Cancer are accepting applications for a one-year fellowship program beginning in July 2026!

New #JITC article: ADI-270: an armored allogeneic gamma delta T cell therapy designed to target CD70-expressing solid and hematologic malignancies https://t.co/Vn1SdSSoiC 🧪

New #JITC article: ADI-270: an armored allogeneic gamma delta T cell therapy designed to target CD70-expressing solid and hematologic malignancies t.co/Vn1SdSSoiC 🧪

Dedicated to #makingcureareality? Join SITC’s vibrant and growing network of research and physician scientists, clinicians, patients, patient advocates, government representatives and industry leaders. Learn more about #SITC: www.sitcancer.org/membership/j... #immunotherapy

YouTube video by Society for Immunotherapy of Cancer Honoring the Life and Legacy of Dr. Zelig Eshhar

The SITC family is heart-broken to learn of the passing of Dr. Zelig Eshhar. His research in CAR T-cell therapy changed the treatment of cancer. SITC was fortunate to recognize Dr. Eshhar’s ground-breaking work in #IO by inducting him into the FAIO. www.youtube.com/watch?v=QzLF...